Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Hit By Surprising Tecentriq Miss In TNBC

Has Improved Survival With Nab-Paclitaxel But Not With Paclitaxel

Executive Summary

Tecentriq is the only checkpoint inhibitor to get approval for first-line TNBC but failure in a second study for that indication will encourage rival Merck & Co with Keytruda nearing approval.

You may also be interested in...



Genentech’s Hopes For Keeping Tecentriq Breast Cancer Claim May Rest With Trial In Early Disease Recurrence

Even though IMpassion132 is enrolling a different population and has a different chemotherapy backbone, it could confirm atezolizumab’s benefit for patients with advanced triple-negative breast cancer whose tumors express PD-L1, agency says ahead of advisory committee meeting on accelerated approval indications with failed confirmatory trials.

Keeping Track: Keytruda Adds TNBC Claim; Finerenone, Brincidofovir, HTX-011 Submitted; CRL For Supernus’ ADHD Drug

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

'A New TNBC Standard Of Care' – Trodelvy Could Vindicate Gilead’s $21bn Buyout

Analysts agree that new Phase III data suggests the antibody-drug conjugate will be a new standard of care in third-line TNBC, with potential in earlier treatment lines and in several other tumor types.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel